JP Morgan 2014 Preview: Investors turn up the heat on biotech and specialty pharma
This article was originally published in Scrip
It's hard to say what will be hotter in San Francisco on 13 January: the unseasonably warm weather expected during the 32nd Annual JP Morgan Healthcare Conference or the lineup of biopharma companies scheduled to present at the yearly industry and investor gathering.
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.